Skip to main content
Listen in: the latest news on Biosimilars! Listen to our new Coffee with ClearScript for the latest news on Biosimilars!

The clear choice in pharmacy benefit management.

Insights Archive

April 3, 2024

GLP-1s, losing weight or losing money?

GLP-1s are a hot topic in health plans due to their high-price tag and coverage complexity. Following up on ClearScript’s recent GLP-1 webinar, this podcast will answer some new questions and provide additional updates about this drug class.

April 3, 2024

Rezdiffra (resmetirom)

On March 14, 2024, drug manufacturer Madrigal Pharmaceuticals announced the approval of Rezdiffra™, a new, first in class oral therapy for nonalcoholic steatohepatitis (NASH). This disease, which impacts an estimated 6-8 million people in the U.S., is underdiagnosed and if left untreated, it can cause serious liver complications. Read more about this approval and its implications.

Biosimilars syringe bottle and syringe

April 3, 2024

Understanding Biosimilar Basics

With Humira® biosimilars expected to have a significant impact in 2024, some ClearScript clients are asking for more information. Here we provide the biosimilar basics and what their increasing presence in the marketplace means to the pharmacy benefit.

March 27, 2024

How will the rise of BIOSIMILARS affect your pharmacy benefit plan?

ClearScript’s Clinical Account Executives, Bryan Milbert, PharmD, and Nicole Christian, PharmD, provide a factual presentation on biosimilars’ history, outlook, and how these products could bend your cost curve including perspectives from plan sponsors, members, and prescribers.

Looking down at a counter with scattered medications and a stethoscope as the "0" in the word 2024.

January 11, 2024

Navigating 2024: Three topics shaping the pharmacy benefit

As we reflect on the developments of 2023 and set our sights on 2024, the pharmacy benefit landscape is undergoing significant transformations. Read on to learn what ClearScript is watching in this evolving and complex field to stay ahead of changes that will impact the pharmacy benefit.

Looking down at a heart-shaped bowl of fruits, vegetables and nuts held in hands. Behind the bowl, slightly out of focus, is a medical clipboard with stethoscope and diabetes devices.

January 11, 2024

New Drug Spotlight: Zepbound

On November 8, 2023, Eli Lilly announced the approval of the newest weight loss drug Zepbound, a much-anticipated formulation of tirzepatide in the high-profile GLP-1 agonist medications class. Used along with reduced calorie diet and exercise, studies have shown Zepbound can lead to significant weight loss.

bottle of spilled pills

October 2, 2023

New Drug Spotlight: Arexvy, Abrysvo, and Beyfortus

In 2023, the U.S. Food & Drug Administration (FDA) approved three new vaccines for the prevention of Respiratory Syncytial Virus (RSV). RSV is a highly contagious, common respiratory virus that typically causes mild cold-like symptoms. However, it can cause serious illness in older adults and infants.